Insider Trading Alert - XCO, DFS And OPK Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, May 1, 2014, 88 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,215.00 to $131,924,000.00.

Highlighted Stocks Traded by Insiders:

EXCO Resources (XCO) - FREE Research Report

Burnett Richard Alan, who is VP & Chief Accounting Officer at EXCO Resources, bought 500 shares at $6.00 on May 1, 2014. Following this transaction, the VP & Chief Accounting Officer owned 87,810 shares meaning that the stake was reduced by 0.57% with the 500-share transaction.

The shares most recently traded at $5.95, down $0.05, or 0.84% since the insider transaction. Historical insider transactions for EXCO Resources go as follows:

  • 4-Week # shares sold: 2.0 million
  • 12-Week # shares sold: 4.3 million
  • 24-Week # shares sold: 4.3 million

The average volume for EXCO Resources has been 5.8 million shares per day over the past 30 days. EXCO Resources has a market cap of $1.7 billion and is part of the basic materials sector and energy industry. Shares are up 19.59% year-to-date as of the close of trading on Wednesday.

EXCO Resources, Inc., an independent oil and natural gas company, is engaged in the acquisition, exploration, exploitation, development, and production of onshore oil and natural gas properties with a focus on shale resource plays in the United States. The stock currently has a dividend yield of 3.91%. The company has a P/E ratio of 51.1. Currently, there are no analysts who rate EXCO Resources a buy, 3 analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on XCO - FREE

TheStreet Quant Ratings rates EXCO Resources as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, generally higher debt management risk and a generally disappointing performance in the stock itself. Get the full EXCO Resources Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Discover Financial Services (DFS) - FREE Research Report

Bush Mary K, who is Director at Discover Financial Services, sold 2,941 shares at $55.33 on May 1, 2014. Following this transaction, the Director owned 52,075 shares meaning that the stake was reduced by 5.35% with the 2,941-share transaction.

The shares most recently traded at $56.02, up $0.69, or 1.23% since the insider transaction. Historical insider transactions for Discover Financial Services go as follows:

  • 4-Week # shares sold: 1,412
  • 12-Week # shares sold: 1,412
  • 24-Week # shares sold: 295,482

The average volume for Discover Financial Services has been 3.2 million shares per day over the past 30 days. Discover Financial Services has a market cap of $26.2 billion and is part of the financial sector and financial services industry. Shares are down 0.38% year-to-date as of the close of trading on Wednesday.

Discover Financial Services, a bank holding company, provides a range of financial products and services in the United States. The company operates in two segments, Direct Banking and Payment Services. The stock currently has a dividend yield of 1.4%. The company has a P/E ratio of 11.5. Currently, there are 14 analysts who rate Discover Financial Services a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DFS - FREE

TheStreet Quant Ratings rates Discover Financial Services as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Discover Financial Services Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Opko Health (OPK) - FREE Research Report

Frost Phillip Md Et Al, who is CEO & Chairman at Opko Health, bought 25,000 shares at $8.22 on May 1, 2014. Following this transaction, the CEO & Chairman owned 140.6 million shares meaning that the stake was reduced by 0.02% with the 25,000-share transaction.

The shares most recently traded at $8.39, up $0.17, or 1.98% since the insider transaction. Historical insider transactions for Opko Health go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 46,730
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 46,730
  • 24-Week # shares bought: 40,000
  • 24-Week # shares sold: 46,730

The average volume for Opko Health has been 3.0 million shares per day over the past 30 days. Opko Health has a market cap of $3.4 billion and is part of the health care sector and health services industry. Shares are down 2.01% year-to-date as of the close of trading on Wednesday.

Opko Health, Inc., a biopharmaceutical and diagnostics company, is engaged in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. Currently, there are 4 analysts who rate Opko Health a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OPK - FREE

TheStreet Quant Ratings rates Opko Health as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and weak operating cash flow. Get the full Opko Health Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

P&G, GE and IBM Need to Innovate; Has Starbucks' Stock Grown Ice Cold?--ICYMI

P&G, GE and IBM Need to Innovate; Has Starbucks' Stock Grown Ice Cold?--ICYMI

Is Best Buy Sleeping With the Enemy With Amazon Partnership?

Is Best Buy Sleeping With the Enemy With Amazon Partnership?

Sprint, T-Mobile Might Have to Do More Than Make Promises to Get Deal Approved

Sprint, T-Mobile Might Have to Do More Than Make Promises to Get Deal Approved

Video: The S&P 500 Is Failing to Make New Highs

Video: The S&P 500 Is Failing to Make New Highs

Dow, S&P 500 and Nasdaq Finish Lower as Apple, P&G Slump

Dow, S&P 500 and Nasdaq Finish Lower as Apple, P&G Slump